Scarica l'app Stockscreener
51.40
0.49%
0.25
Dopo l'orario di chiusura:
52.55
1.15
+2.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Precedente Chiudi:
$51.15
Aprire:
$50.58
Volume 24 ore:
2.11M
Relative Volume:
2.21
Capitalizzazione di mercato:
$5.39B
Reddito:
$628.56M
Utile/perdita netta:
$141.82M
Rapporto P/E:
63.46
EPS:
0.81
Flusso di cassa netto:
$142.60M
1 W Prestazione:
-7.22%
1M Prestazione:
-8.36%
6M Prestazione:
+74.83%
1 anno Prestazione:
+66.45%
Intervallo 1D:
$50.02
$52.34
Intervallo di 1 settimana:
$50.02
$56.46
Portata 52W:
$20.84
$62.22
Corcept Therapeutics Inc Stock (CORT) Company Profile
Nome
Corcept Therapeutics Inc
Settore
Industria
Telefono
650.688.8803
Indirizzo
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Confronta CORT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
51.40 | 5.39B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-06 | Aggiornamento | Truist | Hold → Buy |
| 2023-04-11 | Iniziato | SVB Securities | Market Perform |
| 2023-04-04 | Iniziato | Piper Sandler | Overweight |
| 2023-02-15 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-01 | Downgrade | Truist | Buy → Hold |
| 2022-07-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-06-27 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-02 | Iniziato | Canaccord Genuity | Buy |
| 2022-01-28 | Iniziato | Truist | Buy |
| 2020-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-09-24 | Iniziato | Jefferies | Buy |
| 2019-09-06 | Iniziato | H.C. Wainwright | Buy |
| 2019-02-04 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Reiterato | Stifel | Hold |
| 2018-05-31 | Downgrade | Stifel | Buy → Hold |
| 2018-03-09 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Iniziato | Stifel | Buy |
| 2017-02-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2015-04-21 | Iniziato | FBR Capital | Outperform |
| 2014-01-13 | Downgrade | Stifel | Buy → Hold |
| 2013-08-09 | Downgrade | Janney | Buy → Neutral |
| 2013-08-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-01-06 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Aggiornamento | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Mostra tutto
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
Zacks Research Has Negative Outlook for CORT Q1 Earnings - MarketBeat
Geode Capital Management LLC Grows Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
World Investment Advisors LLC Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept’s dazucorilant fails to slow ALS progression in clinical trial - ALS News Today
Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial - Yahoo Finance
Corcept Therapeutics Incorporated (NASDAQ:CORT) Short Interest Down 7.0% in November - MarketBeat
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism - BioSpace
Relacorilant shows promise in long-term hypercortisolism study - Investing.com
Corcept's Phase 3 Study Shows Breakthrough Blood Pressure Results for Relacorilant in Long-term Treatment - StockTitan
Stifel Financial Corp Buys 20,546 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Shares Rise More Than 60% in Three Months: Here's Why - MSN
State Street Corp Has $162.87 Million Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study - MSN
Community Spotlight: Breakthrough Type 1 Diabetes Walk - AOL
Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes - Yahoo Finance
Korlym shows promise in Cushing's syndrome study By Investing.com - Investing.com Canada
Verition Fund Management LLC Sells 28,931 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes - BioSpace
Corcept Therapeutics Diabetes Drug Korlym Meets Primary Endpoint in Study - MarketWatch
Korlym shows promise in Cushing's syndrome study - Investing.com
Corcept's Korlym Shows Breakthrough Results in Phase 4 Diabetes & Cushing's Trial, Hits Key Endpoint - StockTitan
Corcept Therapeutics Fall 3.5 After ALS Drug Fails Trial - MarketWatch
Corcept Phase 2 study of ALS drug fails to meet primary endpoint (NASDAQ:CORT) - Seeking Alpha
Corcept's ALS trial misses primary goal, notes survival difference By Investing.com - Investing.com Canada
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) - Yahoo Finance
Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight - Yahoo Finance
Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock - Yahoo Finance
Executive Wealth Management LLC Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Tanaka Capital Management Inc. Purchases 11,860 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Two Sigma Advisers LP Has $21.16 Million Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Janus Henderson Group PLC Trims Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High? - MSN
Fmr LLC Boosts Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
What Makes Corcept (CORT) a Good Fit for 'Trend Investing' - Yahoo Finance
Corcept Therapeutics stock soars to all-time high of $61.67 By Investing.com - Investing.com Nigeria
Corcept Therapeutics stock soars to all-time high of $61.67 - Investing.com India
Jacobs Levy Equity Management Inc. Acquires 352,947 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 25% Price Jump - Simply Wall St
Captrust Financial Advisors Sells 19,255 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
BNP Paribas Financial Markets Has $4.63 Million Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) shareholders have earned a 34% CAGR over the last five years - Yahoo Finance
Cushing's Syndrome Market is expected to reach US$ 291.1 million - openPR
Charles Schwab Investment Management Inc. Has $47.51 Million Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Algert Global LLC Increases Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics' chief accounting officer sells $80,031 in stock - Investing.com India
Gary Charles Robb Takes Money Off The Table, Sells $146K In Corcept Therapeutics Stock - Benzinga
Corcept Therapeutics: A Most Promising And Compelling Biotech (NASDAQ:CORT) - Seeking Alpha
Corcept therapeutics executive sells $146,625 in stock By Investing.com - Investing.com Canada
Corcept Therapeutics Inc Azioni (CORT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Corcept Therapeutics Inc Azioni (CORT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Swisher Daniel N JR | Director |
Dec 10 '24 |
Sale |
59.46 |
2,200 |
130,812 |
0 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):